The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.
Abstract
Paricalcitol (19-nor-1alpha-25-dihydroxyvitamin D2), a new vitamin D analog developed for the treatment of secondary hyperparathyroidism, was evaluated in three double-blind, placebo-controlled, dose-escalating, randomized multicenter trials. A total of 78 patients (40 Paricalcitol injection, 38 placebo) achieved treatment phase eligibility, which included intact parathyroid hormone (iPTH) > or = 400 pg/ml, normalized serum calcium levels between 8.0 and 10.0 mg/dl, and calcium x phosphorus product values less than 75. Study end points included a decrease in iPTH of at least 30% or a maximum of five dose escalations. After a 4-wk washout, paricalcitol or placebo was administered intravenously three times per week after dialysis for 12 wk. Study drug was started at a dose of 0.04 microg/kg and was increased by 0.04 microg/kg every 2 wk to a maximal allowable dose of 0.24 microg/kg or until at least a 30% decrease in serum iPTH was achieved. The dose of paricalcitol that decreased iPTH by at least 30% became the maintenance dose. Of 40 patients receiving paricalcitol, 27 (68%) had at least a 30% decrease in serum iPTH for 4 consecutive weeks, compared with three of 38 patients (8%) receiving placebo (P < 0.001). For patients who received 12 wk of treatment with paricalcitol, the levels of iPTH decreased significantly from 795+/-86 to 406+/-106 pg/ml (P < 0.001), whereas the values for PTH were 679+/-41 pg/ml before and 592+/-41 pg/ml after 12 wk of therapy in patients receiving placebo (P=NS). Also, there was a significant difference between treatment groups for the change from baseline PTH levels (P < 0.001). Paricalcitol treatment resulted in a significant reduction in serum alkaline phosphatase from 148+/-23 U/L to 101+/-14 U/L (P < 0.001) in patients treated for 12 wk compared with 120+/-9 U/L to 130+/-11 U/L (P=NS) in patients receiving placebo for 12 wk. Importantly, hypercalcemia did not occur before achieving target serum iPTH levels in any of the paricalcitol-treated patients. There was no significant difference for the change from baseline in serum phosphorus within or between treatment groups. There was no significant difference in adverse events between the paricalcitol and placebo-treated groups. These studies demonstrate that paricalcitol safely and effectively suppresses iPTH levels in hemodialysis patients. This second generation vitamin D analog may have a wider therapeutic window than current vitamin D preparations, and thus may allow reduction in PTH with less hypercalcemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The spectrum of bone disease in end-stage renal failure—An evolving disorder
Sherrard, D. J., Hercz, G., Pei, Y., Maloney, N. A., Greenwood, C., Manuel, A., Saiphoo, C., Fenton, S. S., & Segre, G. V. (1993) · Kidney International · doi:10.1038/ki.1993.64 · Cited by 730
Slatopolsky, E., Weerts, C., Thielan, J., Horst, R., Harter, H., & Martin, K. J. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111639 · Cited by 684
Self-citationRegulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat.
Silver, J., Naveh-Many, T., Mayer, H., Schmelzer, H. J., & Popovtzer, M. M. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112714 · Cited by 536
Silver, J., Russell, J., & Sherwood, L. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4270 · Cited by 495
Renal bone disease 1990: An unmet challenge for the nephrologist
Malluche, H., & Faugere, M.-C. (1990) · Kidney International · doi:10.1038/ki.1990.187 · Cited by 362
Quarles, L. D., Yohay, D. A., Carroll, B. A., Spritzer, C. E., Minda, S. A., Bartholomay, D., & Lobaugh, B. A. (1994) · Kidney International · doi:10.1038/ki.1994.223 · Cited by 249
Cited by
Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects
Christakos, S., Dhawan, P., Verstuyf, A., Verlinden, L., & Carmeliet, G. (2016) · Physiological Reviews · doi:10.1152/physrev.00014.2015 · Cited by 1,957
Bone metabolism and disease in chronic kidney disease
Eknoyan, G., Levin, A., & Levin, N. W. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00905-3 · Cited by 1,286
Block, G. A., & Port, F. K. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70064-3 · Cited by 594
Raggi, P., Chertow, G. M., Torres, P. U., Csiky, B., Naso, A., Nossuli, K., Moustafa, M., Goodman, W. G., Lopez, N., Downey, G., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq725 · Cited by 574
Cunningham, J., Danese, M., Olson, K., Klassen, P., & Chertow, G. M. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00596.x · Cited by 566
Metadata
- Authors
- Martin, K. J., González, E. A., Gellens, M., Hamm, L. L., Abboud, H., & Lindberg, J.
- Venue
- Journal of the American Society of Nephrology
- Published
- 1998-08
- Volume
- 9
- Issue
- 8
- Pages
- 1427-1432
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W1958413320
- Cited by
- 346
- References
- 6
- FWCI
- 14.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. https://app.cochat.ai/papers/10.1681/asn.v981427
- The paper
- Martin, K. J., González, E. A., Gellens, M., Hamm, L. L., Abboud, H., & Lindberg, J. (1998). 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v981427
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.